Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced today that the initial offering period of Johnson & Johnson?s (NYSE: JNJ) tender offer for all the outstanding shares of...
Johnson & Johnson Will Commence Subsequent Offering Period NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) today announced that the initial offering period of...
Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced today the voluntary dismissal by the plaintiff of a class action complaint filed on May 28, 2009 in the Superior Court of the...
NEW BRUNSWICK, N.J., June 17 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under...
NEW BRUNSWICK, N.J., June 5 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ), through a new wholly-owned subsidiary, Kite Merger Sub, Inc., today will commence a cash tender offer to...
Cougar Biotechnology, Inc. (NASDAQ:CGRB) announced that results from ongoing Phase II clinical trials of Cougar?s investigational drug CB7630 (abiraterone acetate) were...
DALLAS, May 26 /PRNewswire/ -- BeaconEquity.com announces availability of stock alerts on companies expected to cover ground in Tuesday's market. Investors can view all of the daily stock...
Access to Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology NEW BRUNSWICK, N.J., and LOS ANGELES, May 21 /PRNewswire-FirstCall/ -- Johnson & Johnson...
Cougar Biotechnology, Inc. (NASDAQ: CGRB), a biotechnology company engaged in the in-license and development of clinical stage cancer drug candidates, today reported its...
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Bank of America and Merrill...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
